Late Melanoma Recurrence Associated with Improved Survival

This article originally appeared here.
Share this content:
Melanoma Recurrence a Decade Later Not Rare
Melanoma Recurrence a Decade Later Not Rare

(HealthDay News) -- Melanoma that recurs over a decade after initial treatment is not uncommon, occurring in about 7% of patients, and is associated with improved survival compared with that seen in patients whose tumors recur earlier, according to a study published in the July issue of the Journal of the American College of Surgeons.

Mark B. Faries, M.D., and colleagues from Saint John's Health Center in Santa Monica, Calif., examined the prevalence of late-recurrence melanoma (occurring more than 10 years after potentially curative treatment) among 4,731 patients diagnosed with melanoma treated at their institution who received at least 10 years of follow-up.

The researchers found that 6.9% of patients exhibited late recurrence, with late recurrence rates of 6.8% at 15 years and 11.3% at 20 years for those with no recurrence at 10 years. After accounting for multiple factors, late recurrence was independently associated with younger age and thinner and node negative tumors. Although late recurrences were often distant, they were associated with improved post-recurrence survival compared with recurrences in patients whose cancers recurred within three years.

"Late melanoma recurrence is not rare," Faries and colleagues conclude. "It occurs more frequently in certain clinical groups and is associated with improved post-recurrence survival."

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs